Oncology Expert Prof. Jeff Geschwind Joins New Phase Scientific Advisory Board
Medical device company New Phase has appointed renowned U.S. cancer expert Professor Jeff Geschwind to its Scientific Advisory Board for oncology.
Minneapolis, USA – Medical device company New Phase announced today the appointment of Professor Jeff Geschwind, M.D., to its Scientific Advisory Board (SAB). Professor Geschwind is a leading figure in interventional oncology and image-guided therapies.
In his new role, Professor Geschwind will engage in discussions with the U.S. Food and Drug Administration (FDA) and support preparations for feasibility studies for New Phase's electromagnetic nanotherapy. He currently serves as the Medical Director for Oncology, Image-Guided Therapy at NAMSA, a major U.S. contract research organization.
"We are thrilled to welcome Professor Geschwind as an official part of New Phase's ongoing work to transform stage IV cancer into a chronic condition," said New Phase co-founder and CEO, Ofer Shalev. "His deep expertise and knowledge in interventional oncology and radiology will be a critical piece in New Phase's ongoing success of making our breakthrough treatment a reality for so many patients."
Previously, Professor Geschwind was the chairman of radiology and biomedical imaging at Yale New Haven Hospital and is widely regarded as a pioneer in interventional oncology, with nearly 300 scientific publications to his name.
New Phase is developing an electromagnetic nanotherapy designed to target and destroy solid tumors without damaging surrounding healthy tissue. The company holds 18 global patents and is advancing its technology through clinical trials with the aim of making this life-extending treatment accessible to patients.